Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST
November 02 2022 - 7:30AM
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage
biopharmaceutical company developing products to improve the
survival and/or quality of life for patients who have an unmet
medical need condition announces today it will host a conference
call and live webcast on November 8, 2022, at 4:30 p.m. EST to
discuss its third quarter 2022 results and provide an update on its
clinical pipeline.
Conference Call Information
To participate in this event, please log-on or
dial-in approximately 5 to 10 minutes before the beginning of the
call.
Date: November 8, 2022Time: 4:30 p.m. ESTToll
Free: 888-506-0062International: 973-528-0011Entry Code: 178912Live
Webcast: https://www.webcaster4.com/Webcast/Page/2572/46906
Conference Call Replay
InformationToll-free: 877-481-4010International:
919-882-2331Replay Passcode: 46906Replay Webcast:
https://www.webcaster4.com/Webcast/Page/2572/46906
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products
with existing clinical evidence of efficacy for patients with unmet
or underserved medical conditions who need treatment options that
improve survival and/or quality of life. The Company uses these
criteria for selection to further develop its pipeline programs to
achieve high-value milestones effectively and efficiently. Active
clinical pipeline programs include: PCS6422 (metastatic colorectal,
breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and
PCS12852 (gastroparesis, functional constipation). The members of
the Processa development team have been involved with more than 30
drug approvals by the FDA (including drug products targeted to
orphan disease conditions) and more than 100 FDA meetings
throughout their careers. For more information, visit the company’s
website at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking
statements. The statements in this press release that are not
purely historical are forward-looking statements which involve
risks and uncertainties. Actual future performance outcomes and
results may differ materially from those expressed in
forward-looking statements. Please refer to the documents filed by
Processa Pharmaceuticals with the SEC, specifically the most recent
reports on Forms 10-K and 10-Q, which identify important risk
factors which could cause actual results to differ from those
contained in the forward-looking statements.
For More Information:
Michael
Floydmfloyd@processapharma.com301-651-4256
Patrick
Lin925-683-3218plin@processapharma.com
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Jul 2023 to Jul 2024